ClavystBio

Thank you to all our partners and friends, especially those who travelled long distances, for joining us at ClavystBio Connects 2023. We look forward to furthering the great connections and rich conversations that day! For those who weren't able to join, here's a short video of the day's highlights. Enjoy! #collaboratetoinnovate #clavystbio #clavystbioconnects

A heartfelt thank you to Minister Dr Tan See Leng for joining us for our inaugural #ClavystBioConnects: Portfolio Day! We’re equally grateful to our Board, Portfolio companies, Partners and friends across the ecosystem for enriching the event with lively discussions and meaningful connections. 🤝 By bringing together brilliant minds across the global life sciences industry, with a shared passion for advancing health impact, we reaffirm our commitment to fostering innovation, accelerating commercialization, and building great companies! Accelerator Life Science Partners Allay Therapeutics Automera Droia Ventures Engine Biosciences Hummingbird Bioscience Leyden Labs Lightstone Ventures MediSix Therapeutics NSG BioLabs Nuevocor Paratus Sciences Polaris Partners Quilt Sunbird Bio #65LAB Evotec BRIDGEs

🚀 Nucleate Ignite VC Series Workshop 3: Mastering Startup Valuation & Deal Considerations 🚀 We wrapped up the final session of the Nucleate Ignite VC Series with Dr. Kim Png from Polaris Partners, diving into the intricacies of startup valuation and key deal considerations. Dr. Png guided us through the essential steps in securing funding, from term sheets to syndicate building, and highlighted the differences in investor and founder perspectives during negotiations. The session covered various types of financing—including venture debt, equity, SAFE, and convertible notes—and how these impact control and ownership. Dr. Png emphasized that valuation is more of an art than a science, providing valuable insights into pre-money and post-money evaluations, round sizes, and tranching. Participants also gained valuable knowledge on capitalization, investor rights, and governance, learning how to structure deals to align with both investor and founder goals. The session concluded with a dive into portfolio management and how VCs stay involved with companies post-investment to ensure growth and success. This entire Nucleate Ignite Venture Capital Series has been an incredible journey, providing early career scientists with a comprehensive understanding of the biotech venture landscape. From the fundamentals of funding stages to deep dives into startup valuation, deal structuring, and portfolio management, each session equipped participants with the tools and insights needed to navigate the complexities of the biotech ecosystem. A huge thank you to our speakers and sponsors ClavystBio and all the participants for making this series a success. Stay tuned for more exciting sessions in the Nucleate Ignite Series! Nucleate team: Ying Tong Yeo, Jessie Wong Ling Ai, Roshni Gupta, Panida Cen, Gloria Chan, Samantha Wong, PhD, Ivan Seah, MBBS/MBA/MPH, Jiaqi Liang, Damien Chua, Shruti Sridhar, Isha Karnik, John Joson Ng, Senuri De Silva, Jashan Singh, Hana Maldivita Tambrin, PhD, Dillon Chew, Aakash Kumar, Diya Srivastava, Dijin Zhang, Devika Menon #NucleateIgnite #Biotech #VentureCapital #StartupValuation #Entrepreneurship #LifeSciences #Innovation #BiotechFunding

🎥 View our latest #ClavystBioConversations for a masterclass in #MedTech venture-building! 🚀 Moderated by ClavystBio’s Yingmin Wang, Lightstone Ventures' Mike Carusi and Allay Therapeutics’ Koon Kiat Teu dive into Allay's exciting growth journey —sharing pivotal lessons, challenges, and insights for entrepreneurs and innovators. Watch the full conversation here: https://lnkd.in/gsd8XTvU #Medtech #Innovation #Entrepreneurship ClavystBio Lightstone Ventures Allay Therapeutics National Health Innovation Centre (NHIC)

We had the pleasure of hosting MSD’s Discovery Leads, Marc Levesque, David Weinstock, Erin Whalen and Director of BD and Licensing Koji Yashiro for a candid conversation on what they are looking for, and how startups can best engage with them. The discussion re-enforced one key point: 𝐢𝐭’𝐬 𝐚𝐥𝐰𝐚𝐲𝐬 𝐚𝐛𝐨𝐮𝐭 𝐬𝐨𝐥𝐢𝐝 𝐬𝐜𝐢𝐞𝐧𝐜𝐞 𝐚𝐧𝐝 𝐩𝐫𝐨𝐝𝐮𝐜𝐭 𝐟𝐢𝐫𝐬𝐭.  Here are our top takeaways: 1.     𝐈𝐭’𝐬 𝐧𝐞𝐯𝐞𝐫 𝐭𝐨𝐨 𝐞𝐚𝐫𝐥𝐲 𝐭𝐨 𝐞𝐧𝐠𝐚𝐠𝐞.   “It’s amazing how many small companies don’t put the time into building those relationships. They are selling themselves short.”   2.     𝐃𝐫𝐢𝐯𝐞 𝐡𝐨𝐦𝐞 𝐭𝐡𝐞 𝐬𝐜𝐢𝐞𝐧𝐜𝐞, 𝐚𝐧𝐝 𝐛𝐞 𝐡𝐨𝐧𝐞𝐬𝐭.  “Have your end product in mind. Know what would de-risk it, be clear about the clinical area and indications you are going for, and what your kill experiment would be.” 3.     𝐃𝐨𝐧’𝐭 𝐟𝐨𝐫𝐠𝐞𝐭 𝐦𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠.   “Having to re-do your manufacturing could add 2 years to the timeline, making it no longer attractive. It could be the difference between a deal and no deal.” And finally, a quick PSA: Send your deck in more than 24 hours ahead of your meeting! The team shared they do read them, and it makes for a more productive meeting. 😊 #clavystbioconversations #biotech #pharma

Wishing everyone a joyous #Deepavali filled with light, love, and laughter. ✨🪔 The ClavystBio Node 1 community celebrated this beautiful festival by coming together to create a vibrant rangoli and share a delicious briyani feast. A special thanks to Automera's Roshni Gupta for her insightful talk on the history and significance of Deepavali, and Jeyapriya Raja Sundaram, PhD for treating us to her mouthwatering homemade vadai! #clavystcommunity #collaboratetoinnovate

We’re thrilled to welcome Anselm T. as he joins our leadership team to build our Digital Health and MedTech segment.  Anselm's extensive background and expertise in venture capital and health technology will be invaluable as we continue to drive meaningful innovations towards global health impact. Learn more about Anselm and the ClavystBio team here: https://lnkd.in/ghWAB_gb

ClavystBio CEO Khoo Shih recently shared her insights on the momentum in Singapore’s life sciences sector with The Straits Times’ Timothy Goh.  “Singapore’s #biomedical industry has a strong foundation, poised for sustainable growth” she said. “Global pharmaceutical companies and investors are attracted by the world-class #innovation, well-trained scientific talent, excellent clinical infrastructure and strong government support. We see tremendous potential in investing and growing biomedical companies from Singapore with global health impact.” Read the full article here [subscriber access]: https://lnkd.in/gFB3Mzqu

What does it take to successfully advance and navigate biotech deals? Join our upcoming ClavystBio Conversation and hear directly from seasoned biotech executives with hands-on experience and an impressive track record in investing, operating and overseeing biotech M&As and business partnerships. Co-organized with Enterprise Singapore, the panel will be followed by a networking session. Don't miss this opportunity to gain insights and connect with speakers Luc Dochez, George Golumbeski, Christina K. Isacson Ph.D., Andreas Wallnoefer, Khoo Shih. and other industry players! Registration closes Fri, 1 Nov. Sign up here: https://lnkd.in/grjf4cnp ClavystBio Enterprise Singapore Droia Ventures Lightstone Ventures #clavystbioconversations #clavystcommunity

Our portfolio company Sunbird Bio bolsters the clinical development of its blood-based diagnostic platform with additional funding from new investors Eli Lilly and Company and EDBI Pte Ltd, alongside existing investors ClavystBio, Polaris Partners and S32.